Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Completed
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Interventions
- Registration Number
- NCT05701007
- Lead Sponsor
- Pfizer
- Brief Summary
Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions:
* What are the demographic and clinical characteristics of metastatic prostate cancer patients?
* How are metastatic prostate cancer patients currently treated and how effective are these treatments?
* How does the development of castration-resistance affect patient outcomes?
* What is the economic burden of metastatic prostate cancer?
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1
Inclusion Criteria
- Diagnosis of prostate cancer between 1/1/2007 - 12/31/2022
- Resident of Pirkanmaa at index date (diagnosis of mCSPC and/or mCRPC)
- Detection of metastatic prostate cancer
Exclusion Criteria
- Prevalent mCSPC and mCRPC patients (mCSPC or mCRPC diagnosis date before 1/1/2014
- Patient has another cancer diagnosis or the patient has received chemotherapy other than docetaxel or cabazitaxel within 2 years of mPC diagnosis.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients diagnosed with metastatic castration sensitive prostate cancer (mCSPC) goserelin - Patients diagnosed with metastatic castration sensitive prostate cancer (mCSPC) leuprorelin - Patients diagnosed with metastatic castration sensitive prostate cancer (mCSPC) triptorelin - Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC) docetaxel - Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC) Lutetium-177 - Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC) Radium-223 - Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC) apalutamide - Patients diagnosed with metastatic castration sensitive prostate cancer (mCSPC) degarelix - Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC) abiraterone - Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC) enzalutamide - Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC) cabazitaxel -
- Primary Outcome Measures
Name Time Method Number of treatments received for metastatic prostate cancer up to 12 years Characteristics of Metastatic Cancer Patients up to 12 years Demographical and clinical variables of patients will be summarized
Time to next treatment (TTNT) up to 12 years Overall Survival (OS) up to 12 years
- Secondary Outcome Measures
Name Time Method Incidence of metastatic castration resistant prostate cancer (mCRPC) up to 12 years Identify factors associated with disease progression to castration resistant Up to 12 years Incidence of metastatic prostate cancer (mPC) Up to 12 years Incidence of metastatic castration sensitive prostate cancer (mCSPC) up to 12 years Time of disease progression from castration sensitive to castration resistant up to 12 years The number of patients per treatment type up to 12 years Health Care resource utilization (HCRU): number of outpatient clinic visits, hospitalization and hospital inpatient days up to 12 years
Trial Locations
- Locations (1)
Pfizer
🇫🇮Helsinki, Finland